As TP53 mutation is the most frequently detected mutation in bladder cancer patients (Lamy et al., 2006), we intend to study whether clustering analysis of data from molecular profiling would define TP53 mutant bladder tumors as a subgroup to help identify some novel individualized treatment methods. The gene discussed is TP53; the disease is urinary bladder carcinoma.